University of Leicester
Browse
A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma..pdf (3.13 MB)

A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma

Download (3.13 MB)
journal contribution
posted on 2016-02-24, 10:43 authored by E. Horvilleur, T. Sbarrato, K. Hill, R. V. Spriggs, M. Screen, P. J. Goodrem, K. Sawicka, L. C. Chaplin, C. Touriol, G. Packham, K. N. Potter, S. Dirnhofer, A. Tzankov, Martin J. S. Dyer, M. Bushell, M. MacFarlane, A. E. Willis
Dysregulated expression of factors that control protein synthesis is associated with poor prognosis of many cancers, but the underlying mechanisms are not well defined. Analysis of the diffuse large B-cell lymphoma (DLBCL) translatome revealed selective upregulation of mRNAs encoding anti-apoptotic and DNA repair proteins. We show that enhanced synthesis of these proteins in DLBCL is mediated by the relief of repression that is normally imposed by structure in the 5'-untranslated regions of their corresponding mRNAs. This process is driven by signaling through mammalian target of rapamycin, resulting in increased synthesis of eukaryotic initiation factor (eIF) 4B complex (eIF4B), a known activator of the RNA helicase eIF4A. Reducing eIF4B expression alone is sufficient to decrease synthesis of proteins associated with enhanced tumor cell survival, namely DAXX, BCL2 and ERCC5. Importantly, eIF4B-driven expression of these key survival proteins is directly correlated with patient outcome, and eIF4B, DAXX and ERCC5 are identified as novel prognostic markers for poor survival in DLBCL. Our work provides new insights into the mechanisms by which the cancer-promoting translational machinery drives lymphomagenesis.

History

Citation

Leukemia, 2014, 28 (5), pp. 1092-1102

Author affiliation

/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Cancer Studies and Molecular Medicine

Version

  • VoR (Version of Record)

Published in

Leukemia

Publisher

Nature Publishing Group

issn

0887-6924

eissn

1476-5551

Acceptance date

2013-10-07

Copyright date

2014

Available date

2016-02-24

Publisher version

http://www.nature.com/leu/journal/v28/n5/full/leu2013295a.html

Language

en